粒体自噬
药物发现
自噬
激活剂(遗传学)
体内
生物信息学
药品
计算生物学
药物开发
神经科学
生物
表型筛选
医学
品脱1
磷脂病
批准的药物
药物靶点
体外
药理学
细胞生物学
线粒体
药物重新定位
钥匙(锁)
作者
Zhipeng Ling,Junping Pan,Xianglu Xiao,Wenfan Wu,Guisi Chen,Fang Shi,Zehuan Chen,Haiyi Zhang,Yuehao Huang,Qing Tang,Qiwei Cai,Shenglong Deng,Zhangming Niu,Shiqi Zhang,Heling Wang,Jianying Zhang,Xuefeng Zhou,Lingyan Mao,Junliang Li,Hongming Chen
标识
DOI:10.1186/s13024-026-00998-2
摘要
Abstract Defective mitophagy is a key pathological risk of Alzheimer’s disease (AD), yet available pharmacological agents capable of restoring mitophagy remain clinically limited, largely due to the lack of tools for drug screening and target identification. To address this, we introduce an integrated platform with three novel artificial intelligence (AI)-enabled approaches—the phenotype-based screening model ‘CellAutoFM’, the drug-likeness predictor ‘ADMET Ranker’, and the target deconvolution method ‘PROCAT’. Using this platform together with wet lab validation, Crassifolin A (JGX-1) is identified as a potent natural product-derived mitophagy inducer; structurally, JGX-1 directly binds to ATP-binding cassette sub-family A member 1 (ABCA1) and sub-family G member 1 (ABCG1), triggering enhanced cholesterol efflux which activates PINK1/Parkin-dependent mitophagy. In both in vitro and in vivo AD laboratory models, JGX-1 reduces amyloid-β and Tau pathologies in an autophagy/mitophagy-dependent manner as these benefits are dramatically blunted with key mitophagy genes knocked down. Collectively, we provide an open-access, reproducible AI-assisted platform for rapid compound screening, drug-likeness evaluation, and potential target prediction to advance drug discovery. Through this paradigm, we unveil modulating the ABCA1/ABCG1-mediated cholesterol-mitophagy pathway as a promising anti-AD strategy, with a novel drug candidate JGX-1 identified.
科研通智能强力驱动
Strongly Powered by AbleSci AI